Alterations in phospholipase D during the development of myocardial disease

Phospholipases in Health and Disease

Volumn 10, Issue , 2014, Pages 381-393

  Tappia, Paramjit S ^a   Dhalla, Naranjan S ^b  

^a ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Congestive heart failure; Diabetic cardiomyopathy; Ischemia reperfusion injury; Phospholipase D; PLD mediated signal transduction; Signal transduction

Indexed keywords

EID: 84969831515     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0464-8_23     Document Type: Chapter

References (102)

1. Exton JH (1994) Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1212:26-42
2. Panagia V, Ou C, Taira Y et al (1991) Phospholipase D activity in subcellular membranes of rat ventricular myocardium. Biochim Biophys Acta 1064:242-250
3. Sadoshima J, Izumo S (1993) Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. Circ Res 73:424-438
4. Ye H, Wolf RA, Kurz T, Corr PB (1994) Phosphatidic acid increases in response to noradrenaline and endothelin-1 in adult rabbit ventricular myocytes. Cardiovasc Res 28: 1828-1834
5. Dhalla NS, Xu YJ, Sheu SS et al (1997) Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol 29:2865-2871
6. 2+ to phosphatidic acid in diabetic rats. Can J Cardiol 12:1092-1098
7. 2+ and cardiac contractile force. Am J Physiol Heart Circ Physiol 271:H651-H659
8. Lamers JM, Eskildsen-Helmond YE, Resink AM et al (1995) Endothelin-1-induced phospholipase C ß and D and protein kinase C isoenzyme signaling leading to hypertrophy in rat cardiomyocytes. J Cardiovasc Pharmacol 26:S100-S103
9. Frohman MA, Morris AJ (1999) Phospholipase D structure and function. Chem Phys Lipids 98:127-140
10. Freyberg Z, Sweeney D, Siddhanta A et al (2001) Intracellular localization of phospholipase D1 in mammalian cells. Mol Biol Cell 12:943-955
11. Park JB, Kim JH, Kim KY et al (2000) Cardiac phospholipase D2 localizes to sarcolemmal membranes and is inhibited by a-actinin in an ADP-ribosylation factor-reversible manner. J Biol Chem 275:21295-21301
12. Hiroyama M, Exton JH (2005) Localization and regulation of phospholipase D2 by ARF6. J Cell Biochem 95:149-164
13. Freyberg Z, Bourgoin S, Shields D (2002) Phospholipase D2 is localized to the rims of the Golgi apparatus in mammalian cells. Mol Biol Cell 13:3930-3942
14. Moon C, Kim H, Kim S et al (2008) Transient expression of Phospholipase D1 during heart development in rats. J Vet Med Sci 70:411-413
15. Hammond SM, Jenco JM, Nakashima S et al (1997) Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-a. J Biol Chem 272:3860-3868
16. Kim JH, Lee SD, Han JM et al (1998) Activation of phospholipase D1 by direct interaction with ADP-ribosylation factor 1 and RalA. FEBS Lett 430:231-235
17. Lee TG, Park JB, Lee SD et al (1997) Phorbol myristate acetate-dependent association of protein kinase C a with phospholipase D1 in intact cells. Biochim Biophys Acta 1347: 199-204
18. Liscovitch M, Chalifa V, Pertile P et al (1994) Novel function of phosphatidylinositol 4,5-bisphosphate as a cofactor for brain membrane phospholipase D. J Biol Chem 269: 21403-21406
19. Malcolm KC, Elliott CM, Exton JH (1996) Evidence for Rho-mediated agonist stimulation of phospholipase D in rat fibroblasts. Effects of Clostridium botulinum C3 exoenzyme. J Biol Chem 271:13135-13139
20. Yamazaki M, Zhang Y, Watanabe H et al (1999) Interaction of the small G protein RhoA with the C terminus of human phospholipase D1. J Biol Chem 274:6035-6038
21. Nataranjan V, Scribner WM, Vepa S (1996) Regulation of phospholipase D by tyrosine kinases. Chem Phys Lipids 24:103-116
22. Exton JH (1998) Phospholipase D. Biochim Biophys Acta 1436:105-115
23. Singer WD, Brown HA, Jiang X, Sternweis PC (1996) Regulation of phospholipase D by protein kinase C is synergistic with ADP-ribosylation factor and independent of protein kinase activity. J Biol Chem 271:4504-4510
24. Sciorra VA, Hammond SM, Morris AJ (2001) Potent direct inhibition of mammalian phospholipase D isoenzymes by calphostin-c. Biochemistry 40:2640-2646
25. Hammond SM, Altshuller YM, Sung TC et al (1995) Human ADP-ribosylation factoractivated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family. J Biol Chem 270:29640-29643
26. Dai J, Williams SA, Ziegelhoffer A, Panagia V (1995) Structure-activity relationship of the effect of cis-unsaturated fatty acids on heart sarcolemmal phospholipase D activity. Prostagland Leuk Essent Fatty Acids 52:167-171
27. Colley WC, Sung TC, Roll R et al (1997) Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr Biol 7:191-201
28. Morris AJ (2007) Regulation of phospholipase D activity, membrane targeting and intracellular trafficking by phosphoinositides. Biochem Soc Symp 74:247-257
29. 2+, protein kinase C, and protein kinase A in hormonal stimulation of phospholipase D in rat hepatocytes. J Biol Chem 269:849-859
30. Kanaho Y, Nishida A, Nozawa Y (1992) Calcium rather than protein kinase C is the major factor to activate phospholipase D in FMLP-stimulated rabbit peritoneal neutrophils. Possible involvement of calmodulin/myosin L chain kinase pathway. J Immunol 149:622-628
31. Kiss Z (1992) Differential effects of platelet-derived growth factor, serum and bombesin on phospholipase D-mediated hydrolysis of phosphatidylethanolamine in NIH 3T3 fibroblasts. Biochem J 285:229-233
32. Kurose H (2003) Ga12 and Ga13 as key regulatory mediator in signal transduction. Life Sci 74:155-161
33. Lopez I, Arnold RS, Lambeth JD (1998) Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J Biol Chem 273:12846-12852
34. Dascher C, Balch WE (1994) Dominant inhibitory mutants of ARF1 block endoplasmic reticulum to Golgi transport and trigger disassembly of the Golgi apparatus. J Biol Chem 269:1437-1448
35. Rumenapp U, Geiszt M, Wahn F et al (1995) Evidence for ADP-ribosylation-factor-mediated activation of phospholipase D by m3 muscarinic acetylcholine receptor. Eur J Biochem 234:240-244
36. Shome K, Nie Y, Romero G (1998) ADP-ribosylation factor proteins mediate agonistinduced activation of phospholipase D. J Biol Chem 273:30836-30841
37. Burgdorf C, Schafer U, Richardt G, Kurz T (2010) U73122, an aminosteroid Phospholipase C inhibitor, is a potent inhibitor of cardiac Phospholipase D by PIP2-dependent mechanism. J Cardiovasc Pharmacol 55:555-559
38. Kukreja RC, Hess ML (1992) The oxygen free radical system: from equations through membrane-protein interactions to cardiovascular injury and protection. Cardiovasc Res 26: 641-655
39. Singal PK, Khaper N, Palace V, Kumar D (1998) The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 40:426-432
40. Müller BA, Dhalla NS (2010) Mechanisms of the beneficial actions of ischemic preconditioning on subcellular remodeling in ischemic-reperfused heart. Curr Cardiol Rev 6: 255-264
41. Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40:239-247
42. Mullarkey CJ, Edelstein D, Brownlee M (1990) Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932-939
43. Giugliano D, Marfella R, Acampora R et al (1998) Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 21:631-636
44. Jain SK, McVie R, Jaramillo JJ et al (1996) The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids 31(suppl):S87-S90
45. Dhalla NS, Pierce GN, Innes IR, Beamish RE (1985) Pathogenesis of cardiac dysfunction in diabetes mellitus. Can J Cardiol 1:263-281
46. Afzal N, Ganguly PK, Dhalla KS et al (1988) Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37:936-942
47. 2+ exchange and Na+-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats. Mol Cell Biochem 188:91-101
48. Williams SA, Tappia PS, Yu CH et al (1997) Subcellular alterations in cardiac phospholipase D activity in chronic diabetes. Prostagland Leuk Essent Fatty Acids 57:95-99
49. Williams SA, Tappia PS, Yu CH et al (1998) Impairment of the sarcolemmal phospholipase D-phosphatidate phosphohydrolase pathway in diabetic cardiomyopathy. J Mol Cell Cardiol 30:109-118
50. Dzau VJ (2001) Tissue angiotensin and pathobiology of vascular disease. Hypertension 37:1047-1052
51. 1 receptor and NADPH oxidase. Hypertension 42:206-212
52. Ortmeyer J, Mohsenin V (1996) Inhibition of phospholipase D and superoxide generation by glucose in diabetic neutrophils. Life Sci 59:255-262
53. Tappia PS, Liu SY, Tong Y et al (2001) Reduction of phosphatidylinositol-4,5-bisphosphate mass in heart sarcolemma during diabetic cardiomyopathy. Adv Exp Med Biol 498: 183-190
54. Mesaeli N, Tappia PS, Suzuki S et al (2000) Oxidants depress the synthesis of phosphatidylinositol 4,5-bisphosphate in heart sarcolemma. Arch Biochem Biophys 382:48-56
55. Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655-673
56. Dhalla NS, Golfman L, Takeda S et al (1999) Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review. Can J Cardiol 15:587-593
57. Dhalla NS, Temsah R (2001) Sarcoplasmic reticulum and cardiac oxidative stress: an emerging target for heart disease. Expert Opin Ther Targets 5:205-217
58. Giordano FJ (2005) Oxygen, oxidative stress, hypoxia and heart failure. J Clin Invest 115: 500-508
59. 2+ pump by oxygen free radicals. Am J Physiol Heart Circ Physiol 257:H804-H811
60. 2+-pump activity by oxygen free radicals. Am J Physiol Heart Circ Physiol 256:H368-H374
61. Kaneko M, Lee SL, Wolf CM, Dhalla NS (1989) Reduction of calcium channel antagonist binding sites by oxygen free radicals in rat heart. J Mol Cell Cardiol 21:935-943
62. Kaneko M, Chapman DC, Ganguly PK et al (1991) Modification of cardiac adrenergic receptors by oxygen free radicals. Am J Physiol Heart Circ Physiol 260:H821-H826
63. Okabe E, Hess ML, Oyama M, Ito H (1983) Characterization of free radical-mediated damage of canine cardiac sarcoplasmic reticulum. Arch Biochem Biophys 225:164-177
64. Otani H, Tanaka H, Inoue T et al (1984) In vitro study on contribution of oxidative metabolism of isolated rabbit heart mitochondria to myocardial reperfusion injury. Circ Res 55: 168-175
65. Peivandi AA, Huhn A, Lehr HA et al (2005) Upregulation of phospholipase D expression and activation in ventricular pressure-overload hypertrophy. J Pharmacol Sci 98:244-254
66. Yamamoto K, Takahashi Y, Mano T et al (2004) N-methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of Phospholipase D as a possible mechanism. Eur Heart J 25:1221-1229
67. Dent MR, Singal T, Dhalla NS, Tappia PS (2005) Expression of phospholipase D isozymes in scar and viable tissue in congestive heart failure due to myocardial infarction. J Cell Mol Med 8:526-536
68. Kasai T, Ohguchi K, Nakashima S et al (1998) Increased activity of oleate-dependent type phospholipase D during actinomycin D-induced apoptosis in Jurkat T cells. J Immunol 161:6469-6474
69. Yamakawa H, Banno Y, Nakashima S et al (2000) Increased phospholipase D2 activity during hypoxia-induced death of PC12 cells: its possible anti-apoptotic role. Neuroreport 11: 3647-3650
70. Tojo A, Onozato ML, Kobayashi N et al (2002) Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 40:834-839
71. Harrison DG, Cai H, Landmesser U, Griendling KK (2003) Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4:51-61
72. Dhalla NS, Shao Q, Panagia V (1998) Remodeling of cardiac membranes during the development of congestive heart failure. Heart Fail Rev 2:261-272
73. Heymes C, Bendall JK, Ratajczak P et al (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164-2171
74. Li JM, Gall NP, Grieve DJ et al (2002) Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40:477-484
75. Yu CH, Panagia V, Tappia PS et al (2002) Alterations of sarcolemmal phospholipase D and phosphatidate phosphohydrolase in congestive heart failure. Biochim Biophys Acta 1584: 65-72
76. Kloner RA, Ellis SG, Lange R, Braunwald E (1983) Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 68:I8-115
77. Freeman BA, Crapo JD (1982) Biology of disease: free radicals and tissue injury. Lab Invest 47:412-426
78. Ferrari R, Alfieri O, Curello S et al (1990) Occurrence of oxidative stress during reperfusion of the human heart. Circulation 81:201-211
79. Hasenfuss G, Meyer M, Schillinger W (1997) Calcium handling proteins in the failing human heart. Basic Res Cardiol 92:87-93
80. Palace V, Kumar D, Hill MF, Khaper N, Singal PK (1999) Regional differences in nonenzymatic antioxidants in the heart under control and oxidative stress conditions. J Mol Cell Cardiol 31:193-202
81. Meerson FZ, Kagan VE, Kozlov Yu P et al (1982) The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res Cardiol 77: 465-485
82. Natarajan V, Scribner VM, Hart CM, Parthasarathy S (1995) Oxidized low density lipoproteinmediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. J Lipid Res 36:2005-2016
83. + exchange in Phospholipase D-treated sarcolemmal vesicles. Am J Physiol Heart Circ Physiol 279: H1179-H1184
84. Tosaki A, Maulik N, Cordis G et al (1997) Ischemic preconditioning triggers phospholipase D signaling in rat heart. Am J Physiol Heart Circ Physiol 273:H1860-H1866
85. Bruhl A, Faldum A, Loffelholz K (2003) Degradation of phosphatidylethanol counteracts the apparent phospholipase D-mediated formation in heart and other organs. Biochim Biophys Acta 1633:84-89
86. Bruhl A, Hafner G, Loffelholz K (2004) Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: no evidence for a role of phospholipase D. Life Sci 75:1609-1620
87. Kurz T, Kemken D, Mier K et al (2004) Human cardiac phospholipase D activity is tightly controlled by phosphatidylinositol 4,5-bisphosphate. J Mol Cell Cardiol 36:225-232
88. Asemu G, Dent MR, Singal T et al (2005) Differential changes in phospholipase D and phosphatidate phosphohydrolase activities in ischemia-reperfusion of rat heart. Arch Biochem Biophys 436:136-144
89. Liu SY, Tappia PS, Dai J et al (1998) Phospholipase A2-mediated activation of phospholipase D in rat heart sarcolemma. J Mol Cell Cardiol 30:1203-1214
90. 2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. J Biol Chem 271:21505-21513
91. Ferrari R, Ceconni C, Curello S et al (1991) Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med 91:95S-105S
92. Gilbert HF (1984) Redox control of enzyme activities by thiol/disulfide exchange. Methods Enzymol 107:330-351
93. Moraru II, Popescu LM, Maulik N et al (1992) Phospholipase D signaling in ischemic heart. Biochim Biophys Acta 1139:148-154
94. Cohen MV, Liu Y, Liu GS et al (1996) Phospholipase D plays a role in ischemic preconditioning in rabbit heart. Circulation 94:1713-1718
95. Trifan OC, Popescu LM, Tosaki A et al (1996) Ischemic preconditioning involves phospholipase D. Ann NY Acad Sci 793:485-488
96. Lecour S, Rochette L, Opie L (2005) TNFa-induced cardioprotection. Cardiovasc Res 65:239-243
97. Tritto I, Ambrosio G (2001) Role of oxidants in the signaling pathway of preconditioning. Antioxid Redox Signal 3:3-10
98. Armstrong SC (2004) Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 61:427-436
99. Eskildsen-Helmond YE, Gho BC, Bezstarosti K et al (1998) Exploration of the possible roles of phospholipase D and protein kinase C in the mechanism of ischemic preconditioning in the myocardium. Ann NY Acad Sci 793:210-225
100. Tappia PS (2007) Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can J Physiol Pharmacol 85:25-41
101. Tappia PS, Singal T (2008) Phospholipid-mediated signaling and heart disease. Subcell Biochem 49:299-324
102. Tappia PS, Dent MR, Dhalla NS (2008) Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med 41:349-361